Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Activated T cells and cytokine-induced CD3(+)CD56(+) killer cells ANNALS OF HEMATOLOGY SCHMIDTWOLF, G. D., Negrin, R. S., SCHMIDTWOLF, I. G. 1997; 74 (2): 51-56

Abstract

Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells.

View details for Web of Science ID A1997WL90200001

View details for PubMedID 9063373